from the United States Court of Appeals for the Federal Circuit
See other cases from the Federal Circuit.
Amendment to Rule 29.6 Corporate Disclosure Statement filed with respect to brief in opposition of respondent Vanda Pharmaceuticals Inc.
The Solicitor General is invited to file a brief in this case expressing the views of the United States.
Letter of Hikma Pharmaceuticals USA Inc., et al. received.
Reply of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
Brief of respondent Vanda Pharmaceuticals USA, Inc. in opposition filed.
Brief amici curiae of The Association for Accessible Medicines and Certain Individual Companies filed.
Brief amici curiae of Intellectual Property and Innovation Professors, Engine Advocacy, et al. filed.
Motion to extend the time to file a response is granted and the time is extended to and including February 12, 2019.
Motion to extend the time to file a response from January 28, 2019 to February 12, 2019, submitted to The Clerk.
Petition for a writ of certiorari filed. (Response due January 28, 2019)
Application (18A461) granted by The Chief Justice extending the time to file until December 27, 2018.
Application (18A461) to extend the time to file a petition for a writ of certiorari from November 12, 2018 to December 27, 2018, submitted to The Chief Justice.
Hikma Pharmaceuticals USA Inc., et al., Petitioner, represented by Steffen Nathanael Johnson
Vanda Pharmaceuticals USA, Inc., Respondent, represented by Nicholas Groombridge
Intellectual Property and Innovation Professors, Engine Advocacy, and The R Street Institute, Amicus Curiae, represented by Phillip Robert Malone
THE ASSOCIATION FOR ACCESSIBLE MEDICINES AND CERTAIN INDIVIDUAL COMPANIES, Amicus Curiae, represented by Douglas Clifford Hochstetler